ARCHIVES

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

NCI’s Weinstein Said He Never Pressured Researcher

November 3, 1995

Conversation With The Cancer Letter: Wicha to Leave Director’s Job at UMich

November 8, 2013

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011

Fluoride Study Update Finds No Increased Risk

October 19, 1990

Foti Receives Del Duca Award; Wake Forest To Hire 60 Faculty.

February 11, 2000

Antoine To Leave As RP Director, Will Join ROB

November 2, 1990